IP Library › Granted Patent US 12,215,147
Granted Patent B2
US 12,215,147 · App. 17/409,639 · Granted Feb 4, 2025

Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody

Inventors: Laurens Kruidenier (San Diego, CA); Mahyar Sabripour (San Diego, CA); Janine Bilsborough (Los Angeles, CA); Dermot P. McGovern (Los Angeles, CA); Dalin Li (Los Angeles, CA)
Assignees: PROMETHEUS BIOSCIENCES, INC.; CEDARS-SINAI MEDICAL CENTER
C07K16/241A61P1/00A61P1/04C07K16/2875C12Q1/6883A61K2039/505C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,215,147
App. No.
17/409,639
Granted
Feb 4, 2025
Kind
B2
Abstract

Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.

Claims (53)

1. A method of selecting a subject having inflammatory bowel disease (IBD) for treatment with an anti-tumor necrosis factor-like cytokine 1A (anti-TL1A) antibody or an antigen-binding fragment thereof, the method comprising:

(a) providing a biological sample from a subject having IBD to determine presence of three or more polymorphisms selected from the group consisting of: rs1892231, rs56124762, rs6478109, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs16901748, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs1690492, rs420726, rs7759385, rs2548147, rs7278257, rs11221332, rs11558819, rs2329718, rs2070559, rs2070560, and any proxy polymorphism in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85;

(b) selecting a subject determined to have the presence of the three or more polymorphisms in (a), wherein the presence of the three or more polymorphisms is indicative of a positive therapeutic response to a treatment with an anti-TL1A antibody or an antigen-binding fragment thereof with a positive predictive value (PPV) of at least about 70%; and

(c) administering a therapeutically effective amount of the anti-TL1A antibody or antigen-binding fragment thereof to the subject selected in (b).

2. The method of claim 1 , wherein the presence of the three or more polymorphisms is determined with a method selected from the group consisting of Polymerase Chain Reaction (PCR), automated sequencing, array genotyping, allele-specific hybridization, self-sustained sequence replication, and next-generation sequencing.

3. The method of claim 2 , wherein the presence of the three or more polymorphisms is determined with PCR.

4. The method of claim 3 , wherein the PCR comprises quantitative polymerase chain reaction (qPCR), reverse transcription PCR (RT-PCR), or a combination thereof.

5. The method of claim 1 , wherein the PPV is at least about 75%.

6. The method of claim 1 , wherein the presence of the three or more polymorphisms is predictive for responding to the anti-TL1A antibody or antigen-binding fragment thereof with a specificity of at least about 70%.

7. The method of claim 1 , wherein the three or more polymorphisms are on a plurality of genes selected from the group consisting of TL1A, THADA Armadillo Repeat Containing (THADA), XK Related 6 (XKR6), Transcription Factor (ETS1), C-Type Lectin Domain Containing 16A (CLEC16A), Suppressor Of Cytokine Signaling 1 (SOCS1), Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2), Inducible T Cell Costimulator Ligand (ICOSLG), Janus Kinase 2 (JAK2), Catenin Delta 2 (CTNND2), Regulator Of G Protein Signaling 7 (RGS7), RNA Binding Fox-1 Homolog 1 (RBFOX1), RNA Binding Motif Protein 17 (RBM17), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), Ecto-NOX Disulfide-Thiol Exchanger 1 (ENOX1), Coiled-Coil Domain Containing 122 (CCDC122), Regulator Of Telomere Elongation Helicase 1 (RTEL1), TNF Receptor Superfamily Member 6b (TNFRSF6B), GLIS Family Zinc Finger 3 (GLIS3), Solute Carrier Family 1 Member 1 (SLC1A1), IKAROS Family Zinc Finger 2 (IKZF2), Long Intergenic Non-Protein Coding RNA 1031 (LINC01031), Fatty Acyl-CoA Reductase 1 (FAR1), Spondin 1 (SPON1), Long Intergenic Non-Protein Coding RNA 1150 (LINC01150), Pleckstrin Homology, MyTH4 And FERM Domain Containing H2 (PLEKHH2), Plexin A2 (PLXNA2), MIR205 Host Gene (MIR205HG), PR/SET Domain 1 (PRDM1), Autophagy Related 5 (ATG5), Long Intergenic Non-Protein Coding RNA 603 (LINC00603), Prostaglandin E Receptor 4 (PTGER4), and Myotubularin Related Protein 9 (MTMR9), and combinations thereof.

8. The method of claim 1 , wherein the three or more polymorphisms comprise rs6478109.

9. The method of claim 1 , wherein the three or more polymorphisms comprises a minor allele at rs6478109.

10. The method of claim 9 , wherein the minor allele at rs6478109 is Adenine (A) or Thymine (T).

11. The method of claim 1 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs7278257, rs2070557, rs7935393, rs9806914, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

12. The method of claim 1 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs7935393, rs9806914, rs16901748, rs2070557, rs7278257, rs2297437, rs1892231, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

13. The method of claim 1 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs16901748, rs2297437, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

14. The method of claim 1 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs2070557, rs7935393, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

15. The method of claim 1 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs7278257, rs7935393, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

16. The method of claim 1 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs9806914, rs1892231, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

17. The method of claim 1 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs7278257, rs16901748, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

18. The method of claim 17 , wherein the proxy polymorphism for rs7278257 is rs56124762.

19. The method of claim 1 , wherein the IBD is Crohn's disease (CD).

20. The method of claim 19 , wherein the CD is moderate to severe CD.

21. The method of claim 1 , wherein the IBD is ulcerative colitis (UC).

22. The method of claim 21 , wherein the UC is moderate to severe UC.

23. The method of claim 1 , wherein the three or more polymorphisms are 4, 5, 6, 7, or 8 polymorphisms.

24. A method comprising:

(a) contacting genetic materials in a biological sample obtained from a subject having inflammatory bowel disease (IBD) with one or more nucleic acid primer pairs having forward and reverse primers capable of hybridizing to one or more target nucleic acid sequences, the one or more target nucleic acid sequences collectively comprising chromosome positions of three or more polymorphisms selected from the group consisting of: rs1892231, rs56124762, rs6478109, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs16901748, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs1690492, rs420726, rs7759385, rs2548147, rs7278257, rs11221332, rs11558819, rs2329718, rs2070559, rs2070560, and any proxy polymorphism in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85;

(b) amplifying the target nucleic acid sequences by polymerase chain reactions with the nucleic acid primer pairs of (a);

(c) inputting results from (b) into a computer system; and

(d) analyzing the results of (b) via the computer system to determine the presence in the target nucleic acid sequences of the three or more polymorphisms of step (a),

wherein the presence of the three or more polymorphisms is indicative of a positive therapeutic response to a treatment with an anti-tumor necrosis factor-like cytoking 1A (anti-TL1A) antibody or an antigen-binding fragment thereof with a positive predictive value (PPV) of at least about 70%, and wherein the computer system comprises a storage unit configured to store the three or more polymorphisms.

25. The method of claim 24 , further comprising before step (c) contacting the target nucleic acid sequences with a plurality of probes to detect the three or more polymorphisms of step (a).

26. The method of claim 24 , wherein the chromosome positions of rs1892231, rs56124762, rs6478109, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs16901748, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs1690492, rs420726, rs7759385, rs2548147, rs7278257, rs11221332, rs11558819, rs2329718, rs2070559, and rs2070560 are provided in Table 5 and Table 10.

27. The method of claim 24 , wherein the PPV is at least about 75%.

28. The method of claim 24 , wherein the presence of the three or more polymorphisms is predictive for responding to the anti-TL1A antibody or antigen-binding fragment thereof with a specificity of at least about 70%.

29. The method of claim 24 , wherein the three or more polymorphisms are on a plurality of genes selected from the group consisting of TL1A, THADA Armadillo Repeat Containing (THADA), XK Related 6 (XKR6), Transcription Factor (ETS1), C-Type Lectin Domain Containing 16A (CLEC16A), Suppressor Of Cytokine Signaling 1 (SOCS1), Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2), Inducible T Cell Costimulator Ligand (ICOSLG), Janus Kinase 2 (JAK2), Catenin Delta 2 (CTNND2), Regulator Of G Protein Signaling 7 (RGS7), RNA Binding Fox-1 Homolog 1 (RBFOX1), RNA Binding Motif Protein 17 (RBM17), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), Ecto-NOX Disulfide-Thiol Exchanger 1 (ENOX1), Coiled-Coil Domain Containing 122 (CCDC122), Regulator Of Telomere Elongation Helicase 1 (RTEL1), TNF Receptor Superfamily Member 6b (TNFRSF6B), GLIS Family Zinc Finger 3 (GLIS3), Solute Carrier Family 1 Member 1 (SLC1A1), IKAROS Family Zinc Finger 2 (IKZF2), Long Intergenic Non-Protein Coding RNA 1031 (LINC01031), Fatty Acyl-CoA Reductase 1 (FAR1), Spondin 1 (SPON1), Long Intergenic Non-Protein Coding RNA 1150 (LINC01150), Pleckstrin Homology, MyTH4 And FERM Domain Containing H2 (PLEKHH2), Plexin A2 (PLXNA2), MIR205 Host Gene (MIR205HG), PR/SET Domain 1 (PRDM1), Autophagy Related 5 (ATG5), Long Intergenic Non-Protein Coding RNA 603 (LINC00603), Prostaglandin E Receptor 4 (PTGER4), and Myotubularin Related Protein 9 (MTMR9).

30. The method of claim 24 , wherein the three or more polymorphisms comprise rs6478109.

31. The method of claim 24 , wherein the three or more polymorphisms comprises a minor allele at rs6478109.

32. The method of claim 31 , wherein the minor allele at rs6478109 is Adenine (A) or Thymine (T).

33. The method of claim 24 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs7278257, rs2070557, rs7935393, rs9806914, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

34. The method of claim 24 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs7935393, rs9806914, rs16901748, rs2070557, rs7278257, rs2297437, rs1892231, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

35. The method of claim 24 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs16901748, rs2297437, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

36. The method of claim 24 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs2070557, rs7935393, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

37. The method of claim 24 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs7278257, rs7935393, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

38. The method of claim 24 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs9806914, rs1892231, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

39. The method of claim 24 , wherein the three or more polymorphisms are selected from the group consisting of rs6478109, rs7278257, rs16901748, and any proxy polymorphisms that are in linkage disequilibrium with any of the foregoing as determined with an R 2 of at least 0.85.

40. The method of claim 39 , wherein the proxy polymorphism for rs7278257 is rs56124762.

41. The method of claim 24 , wherein the IBD is Crohn's disease (CD).

42. The method of claim 41 , wherein the CD is moderate to severe CD.

43. The method of claim 24 , wherein the IBD is ulcerative colitis (UC).

44. The method of claim 43 , wherein the UC is moderate to severe UC.

45. The method of claim 24 , wherein the three or more polymorphisms are 4, 5, 6, 7, or 8 polymorphisms.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2022
From: BILSBOROUGH, JANINE; MCGOVERN, DERMOT P.; LI, DALIN
To: CEDARS-SINAI MEDICAL CENTER
Reel/Frame 059345/0597 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2022
From: KRUIDENIER, LAURENS; SABRIPOUR, MAHYAR
To: PROMETHEUS BIOSCIENCES, INC.
Reel/Frame 059345/0931 →
Continuity (4)
Continuation 17118441 · Dec 10, 2020
Continuation PCTUS2020032679 · May 13, 2020
Provisional Application 62847798 · May 14, 2019
Related Publication 20230018729A1 · Jan 19, 2023
References Cited (284)
US 4229447A · Porter · 1980 [cited by applicant]
US 4476116A · Anik · 1984 [cited by applicant]
US 4596795A · Pitha · 1986 [cited by applicant]
US 4755386A · Hsiao et al. · 1988 [cited by applicant]
US 5011692A · Fujioka et al. · 1991 [cited by applicant]
US 5017381A · Maruyama et al. · 1991 [cited by applicant]
US 5116817A · Anik · 1992 [cited by applicant]
US 5229135A · Philippon et al. · 1993 [cited by applicant]
US 5739136A · Ellinwood, Jr. et al. · 1998 [cited by applicant]
US 5739163A · Cain et al. · 1998 [cited by applicant]
US 5837284A · Mehta et al. · 1998 [cited by applicant]
US 5840329A · Bai · 1998 [cited by applicant]
US 5858401A · Bhalani et al. · 1999 [cited by applicant]
US 6391452B1 · Antonsen et al. · 2002 [cited by applicant]
US 6667048B1 · Lambert et al. · 2003 [cited by applicant]
US 6960563B2 · Egbaria et al. · 2005 [cited by applicant]
US 7531310B2 · Feder et al. · 2009 [cited by applicant]
US 7838239B2 · Mitsuhashi et al. · 2010 [cited by applicant]
US 8301232B2 · Albert et al. · 2012 [cited by applicant]
US 8463553B2 · Lois · 2013 [cited by applicant]
US 8766034B2 · Shih et al. · 2014 [cited by applicant]
US 9305137B1 · Targan et al. · 2016 [cited by applicant]
US 9332741B2 · Shih et al. · 2016 [cited by applicant]
US 9580752B2 · Rotter et al. · 2017 [cited by applicant]
US 9732385B2 · Barken et al. · 2017 [cited by applicant]
US 9784748B2 · Wang et al. · 2017 [cited by applicant]
US 9902996B2 · Dubinsky · 2018 [cited by applicant]
US 10086072B2 · Singh et al. · 2018 [cited by applicant]
US 10261098B2 · Bielekova et al. · 2019 [cited by applicant]
US 10273542B2 · Hackney et al. · 2019 [cited by applicant]
US 10316083B2 · Michelsen et al. · 2019 [cited by applicant]
US 10322174B2 · Bilsborough et al. · 2019 [cited by applicant]
US 10338083B2 · Westin et al. · 2019 [cited by applicant]
US 10349888B2 · Muniz · 2019 [cited by applicant]
US 10385398B2 · Hakonarson et al. · 2019 [cited by applicant]
US 10407725B2 · Hakonarson et al. · 2019 [cited by applicant]
US 10458996B1 · Kokkotou · 2019 [cited by applicant]
US 10477354B2 · Patel et al. · 2019 [cited by applicant]
US 10544459B2 · Targan et al. · 2020 [cited by applicant]
US 10571467B2 · Singh et al. · 2020 [cited by applicant]
US 10626180B2 · McGovern et al. · 2020 [cited by applicant]
US 10633449B2 · Shih et al. · 2020 [cited by applicant]
US 10635787B2 · Hanusiak et al. · 2020 [cited by applicant]
US 10668185B2 · Watkins et al. · 2020 [cited by applicant]
US 10669587B2 · Hackney et al. · 2020 [cited by applicant]
US 10689439B2 · Watkins et al. · 2020 [cited by applicant]
US 10877049B2 · Bielekova et al. · 2020 [cited by applicant]
US 10961581B2 · Garcia-Blanco et al. · 2021 [cited by applicant]
US 11053251B2 · Higuchi · 2021 [cited by applicant]
US 11111539B2 · Hakonarson et al. · 2021 [cited by applicant]
US 11136386B2 · Kruidenier et al. · 2021 [cited by applicant]
US 11160863B2 · Singh et al. · 2021 [cited by applicant]
US 11180565B2 · McGovern et al. · 2021 [cited by applicant]
US 11186872B2 · Gonsky et al. · 2021 [cited by applicant]
US 11236393B2 · Dubinsky et al. · 2022 [cited by applicant]
US 11261493B2 · Hackney et al. · 2022 [cited by applicant]
US 11266730B2 · Faustman · 2022 [cited by applicant]
US 11268149B2 · Targan et al. · 2022 [cited by applicant]
US 11292848B2 · Watkins et al. · 2022 [cited by applicant]
US 11312768B2 · Michelsen et al. · 2022 [cited by applicant]
US 11434296B2 · Shih et al. · 2022 [cited by applicant]
US 11440954B2 · Watkins et al. · 2022 [cited by applicant]
US 20030153063A1 · Feder et al. · 2003 [cited by applicant]
US 20030198640A1 · Yu et al. · 2003 [cited by applicant]
US 20030224400A1 · Barber et al. · 2003 [cited by applicant]
US 20090317388A1 · Burkly et al. · 2009 [cited by applicant]
US 20100136543A1 · Georges et al. · 2010 [cited by applicant]
US 20100190162A1 · Rotter et al. · 2010 [cited by applicant]
US 20100240043A1 · Rotter et al. · 2010 [cited by applicant]
US 20110033486A1 · Abbas et al. · 2011 [cited by applicant]
US 20110160085A1 · Li et al. · 2011 [cited by applicant]
US 20110177502A1 · Hakonarson et al. · 2011 [cited by applicant]
US 20140154275A1 · Abbas et al. · 2014 [cited by applicant]
US 20150132311A1 · Arch et al. · 2015 [cited by applicant]
US 20150301055A1 · Spetzler · 2015 [cited by applicant]
US 20160090629A1 · McGovern · 2016 [cited by applicant]
US 20160215046A1 · Michelsen et al. · 2016 [cited by applicant]
US 20170051351A1 · Hakonarson et al. · 2017 [cited by applicant]
US 20170051352A1 · Hakonarson et al. · 2017 [cited by applicant]
US 20170166967A1 · Rotter et al. · 2017 [cited by applicant]
US 20170185737A1 · Kovacs · 2017 [cited by applicant]
US 20170242043A1 · Bielekova et al. · 2017 [cited by applicant]
US 20180110855A1 · Bilsborough et al. · 2018 [cited by applicant]
US 20180230543A1 · McGovern · 2018 [cited by applicant]
US 20180284010A1 · Scarcelli et al. · 2018 [cited by applicant]
US 20180305459A1 · McGovern et al. · 2018 [cited by applicant]
US 20190070166A1 · Postrel · 2019 [cited by applicant]
US 20190194754A1 · McGovern et al. · 2019 [cited by applicant]
US 20190211400A1 · Rotter et al. · 2019 [cited by applicant]
US 20190247498A1 · Bilsborough et al. · 2019 [cited by applicant]
US 20190256913A1 · Hackney et al. · 2019 [cited by applicant]
US 20190265254A1 · Bielekova et al. · 2019 [cited by applicant]
US 20200080152A1 · Hakonarson et al. · 2020 [cited by applicant]
US 20200157203A1 · Watkins et al. · 2020 [cited by applicant]
US 20200255510A1 · Watkins et al. · 2020 [cited by applicant]
US 20200318066A1 · Sharei et al. · 2020 [cited by applicant]
US 20200325538A1 · Hackney et al. · 2020 [cited by applicant]
US 20200362025A1 · Kruidenier et al. · 2020 [cited by applicant]
US 20210001849A1 · Miura · 2021 [cited by applicant]
US 20210038709A1 · Loughhead et al. · 2021 [cited by applicant]
US 20210070871A1 · Watkins et al. · 2021 [cited by applicant]
US 20210093718A1 · Bilsborough et al. · 2021 [cited by applicant]
US 20210122828A1 · Watkins et al. · 2021 [cited by applicant]
US 20210180133A1 · Garcia-Blanco et al. · 2021 [cited by applicant]
US 20210223265A1 · Stappenbeck et al. · 2021 [cited by applicant]
US 20210325387A1 · Shalek et al. · 2021 [cited by applicant]
US 20210371931A1 · McGovern · 2021 [cited by applicant]
US 20210382050A1 · Shea et al. · 2021 [cited by applicant]
US 20220056529A1 · Hakonarson et al. · 2022 [cited by applicant]
US 20220096629A1 · Singh et al. · 2022 [cited by applicant]
US 20220112625A1 · Postrel · 2022 [cited by applicant]
US 20220186314A1 · Hackney et al. · 2022 [cited by applicant]
US 20220193215A1 · Faustman · 2022 [cited by applicant]
US 20220259320A1 · Watkins et al. · 2022 [cited by applicant]
US 20220260565A1 · Underhill et al. · 2022 [cited by applicant]
US 20220291238A1 · Li et al. · 2022 [cited by applicant]
US 20230192835A1 · Watkins et al. · 2023 [cited by applicant]
US 20230272061A1 · Kruidenier et al. · 2023 [cited by applicant]
US 20230272098A1 · Kruidenier et al. · 2023 [cited by applicant]
US 20230381308A1 · Bilsborough et al. · 2023 [cited by applicant]
EP 2005175B1 · 2011 [cited by applicant]
EP 2257643B1 · 2015 [cited by applicant]
WO WO02053596A2 · 2002 [cited by applicant]
WO WO02053598A2 · 2002 [cited by applicant]
WO WO02059264A2 · 2002 [cited by applicant]
WO WO2007117611A2 · 2007 [cited by applicant]
WO WO2008106451A2 · 2008 [cited by applicant]
WO WO2008107389A1 · 2008 [cited by applicant]
WO WO2009052512A2 · 2009 [cited by applicant]
WO WO2009105590A2 · 2009 [cited by applicant]
WO WO2012154987A1 · 2012 [cited by applicant]
WO WO2013074676A2 · 2013 [cited by applicant]
WO WO2014186750A2 · 2014 [cited by applicant]
WO WO2015136446A1 · 2015 [cited by applicant]
WO WO2015148809A1 · 2015 [cited by applicant]
WO WO2016028699A2 · 2016 [cited by applicant]
WO WO2016028699A3 · 2016 [cited by applicant]
WO WO2016028699A8 · 2016 [cited by applicant]
WO WO2017035010A1 · 2017 [cited by applicant]
WO WO2017035017A1 · 2017 [cited by applicant]
WO WO2017059132A1 · 2017 [cited by applicant]
WO WO2017106383A1 · 2017 [cited by applicant]
WO WO2017189846A1 · 2017 [cited by applicant]
WO WO2018081074A1 · 2018 [cited by applicant]
WO WO2019018440A1 · 2019 [cited by applicant]
WO WO2019178005A2 · 2019 [cited by applicant]
WO WO2019178005A3 · 2019 [cited by applicant]
WO WO2019209995A2 · 2019 [cited by applicant]
WO WO2020081186A1 · 2020 [cited by applicant]
WO WO2020082090A1 · 2020 [cited by applicant]
WO WO2020112890A1 · 2020 [cited by applicant]
WO WO2020163715A1 · 2020 [cited by applicant]
WO WO2020176789A1 · 2020 [cited by applicant]
WO WO2020232125A1 · 2020 [cited by applicant]
WO WO2020242976A1 · 2020 [cited by applicant]
WO WO2021016090A1 · 2021 [cited by applicant]
WO WO2021081365A1 · 2021 [cited by applicant]
WO WO2021108694A1 · 2021 [cited by applicant]
WO WO2021247548A1 · 2021 [cited by applicant]
WO WO2021247770A1 · 2021 [cited by applicant]
WO WO2021260577A2 · 2021 [cited by applicant]
WO WO2022087313A1 · 2022 [cited by applicant]
WO WO2022091085A1 · 2022 [cited by applicant]
WO WO2022103961A1 · 2022 [cited by applicant]
WO WO2022119842A1 · 2022 [cited by applicant]
WO WO2022140283A1 · 2022 [cited by applicant]
WO WO2022178158A1 · 2022 [cited by applicant]
WO WO2022178159A1 · 2022 [cited by applicant]
WO WO2022187196A1 · 2022 [cited by applicant]
WO WO2022232253A1 · 2022 [cited by applicant]
https://www.genecards.org/cgi-bin/carddisp.pl?gene=RSPO1 (viewed on the internet Aug. 11, 2023). [cited by examiner]
https://www.genecards.org/cgi-bin/carddisp.pl?gene=JAK2 (viewed on the internet Aug. 11, 2023). [cited by examiner]
Altschul et al., Basic local alignment search tool, J mol. Boil, 1990, 215:403-410. [cited by applicant]
Altschul et al. Gapped Blast and PSI-Blast: a new generation of protein database search programs. Nucleic Acids Res. 25:3389-3402 (1997). [cited by applicant]
Barrett et al.: Constitutive TL1A Expression under Colitogenic Condition Modulates the Severity and Location of Gut Mucosal Inflammation and Induces Fibrostenosis, American Journal of Pathology, 180(2):636-649 (2012). [cited by applicant]
Behravan et al.: Machine learning identifies interacting genetic variants contributing to breast cancer risk: A case study in Finnish cases and controls. Sci Rep. 8:13149 (2018). [cited by applicant]
Breuer et al.: Detecting significant genotype-phenotype association rules in bipolar disorder: market research meets complex genetics. International Journal of Bipolar Disorders. 6(24):10 pages (2018). [cited by applicant]
Chatterjee et al.: Developing and evaluating polygenic risk prediction models for stratified disease prevention.Nature Reviews, Genetics. pp. 1-15 (2016). [cited by applicant]
Choi et al.: A guide to performing Polygenic Risk Score analyses. bioRxiv. 22 pages (2018) http://dx.doi.org/10.1101/416545. [cited by applicant]
DbSNP Short Genetic Variations Submitted SNP(ss). Details: ss112518351 Mar. 29, 2020 [online]. Retrieved Oct. 5, 2020 URL:https://www.ncbi.nim.nih.gov/projects/SNP/snp_ss.cgi?subsnp_id=ss112518351. [cited by applicant]
DbSNP Short Genetic Variations Submitted SNP(ss). Details: ss226749241. Jul. 20, 2011 [online] Retrieved Oct. 5, 2020. URL:https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ss.cgi?subsnp_id=ss226749241dbSNP Short Genetic Va… [cited by applicant]
De Lange et al.: Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet.: 49(2):256-261 (2017). [cited by applicant]
Ellinghaus et al.: Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat. Genet. 48(5):510-518 (2016). [cited by applicant]
Golumbeanu et al.: Clustering time series gene expression data with TMixClusT. Department of Biosystems Science and Engineering, ETH Zuerich, Switzerland. 16 pages (2018). [cited by applicant]
Herro et al.: TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling. J Immunol. 205(9):2414-2422 (2020) doi: 10.4049/jimmunol.2000665. Epub Sep. 21, 2020. [cited by applicant]
Huang et al.: Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature. 547(7662):173-178 (2017). [cited by applicant]
Jostins et al.: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature; 491/7422:119-124 (2012). [cited by applicant]
Landers et al.: Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens; Gastroenterology; 123:689-699 (2002). [cited by applicant]
Li et al.: Late-Onset Crohn's Disease is a Subgroup Distinct in Genetic and Behavioral Risk Factors with UC-Like Characteristics. Inflamm Bowel Dis. 12;24(11):2413-2422 (2018). [cited by applicant]
Liu et al.: Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations; Nature Genetics; 47, 979-986 (2015). [cited by applicant]
Machiela et al.: LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 31(21):3555-3557 (2015). [cited by applicant]
Medrano et al. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab. Human Immunology 75(1):71-75 (2014). [cited by applicant]
NCBI dbSNP Short Genetic Variations Reference SNP (rs) Report for rs1892231. Jan. 25, 2009 submission. [online] Retrieved Oct. 5, 2020. URL:https://www.ncbi.nlm.nih.gov/snp/rs1892231#submissions. [cited by applicant]
NCBI dbSNP Short Genetic Variations Reference SNP (rs) Report for rs56124762. Jan. 25, 2009 submission [online] Retrieved Oct. 5, 2020 URL:https://www.ncbi.nlm.nih.gov/snp/rs56124762#submissions. [cited by applicant]
Ollech: Efficacy and safety of induction therapy with calcineurin inhibitors followed by maintenance therapy with vedolizumab in severe ulcerative colitis: a large patient cohort with long-term follow-up. Abstracts of t… [cited by applicant]
PCT/US2020/032679 International Search Report and Written Opinion dated Oct. 22, 2020. [cited by applicant]
PCT/US2020/032679 Invitation to Pay Additional Fees dated Aug. 24, 2020. [cited by applicant]
Pierik et al. Tumour Necrosis Factor-a Receptor 1 and 2 Polymorphisms in Inflammatory Bowel Disease and their Association with Response to Infliximab. Alimentary Pharmacology & Therapeutics 20(3):303-310 (2004). [cited by applicant]
Prometheus Biosciences, Inc. Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Feb. 19, 2021 (246 pages). [cited by applicant]
Remington: The Science and Practice of Pharmacy. 21st Edition, Lippincott Williams & Wilkins (2005). [cited by applicant]
Safety, Efficacy, and Tolerability Study of PF-0648064 in Subjects with Moderate to Sever Ulcerative Colitis. Phase II for PF-06480605 (Pfizer, https://clinicaltrials.gov/ct2/show/NCT02840721). [cited by applicant]
Saxon et al., A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin. Immunol. 86:202-210 (1990). [cited by applicant]
Shih et al: Reversal of Murine Colitis and Fibrosis by Neutralizing TL1A Antibody: Potential Novel Therapy to Alter Natural History of Crohn's Disease. Gastroenterology 142(5): s84 (2012). [cited by applicant]
Singh et al. Encyclopedia of Pharmaceutical Technology 2nd Ed. pp. 754-757 (2002). [cited by applicant]
Torkamani et al.: The personal and clinical utility of polygenic risk scores. Nature Reviews, Genetics. 10 pages (2018). [cited by applicant]
U.S. Appl. No. 17/118,441 Final Office Action dated Jun. 25, 2021. [cited by applicant]
U.S. Appl. No. 17/118,441 Office Action dated Mar. 10, 2021. [cited by applicant]
U.S. Appl. No. 17/118,441 Restriction Requirement dated Feb. 8, 2021. [cited by applicant]
Yamazaki et al., Single nucleotide polymorphisms in TNFSF15 confers susceptibility to Crohn's disease. Hum Mol Genet 14:3499-3506 (2005). [cited by applicant]
Yu et al.: Downregulation of VEGF and upregulation of TL1A expression induce HUVEC apoptosis in response to high glucose stimuli. Mol Med Rep. 13(4):3265-72 (2016) doi: 10.3892/mmr.2016.4924. Epub Feb. 22, 2016. [cited by applicant]
ClinicalTrials.gov website: A Phase 2 Safety and Efficacy Study of PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis (ARTEMIS-UC) ClinicalTrials.gov https://classic.clinicaltrials.gov/ct2/show/NCT… [cited by applicant]
ClinicalTrials.gov website:A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease (APOLLO-CD) ClinicalTrials.gov https://classic.clinicaltrials.gov/ct2/s… [cited by applicant]
Michelsen et al., IBD-Associated Tl 1A Gene (TNFSF15) Haplotypes Determine Increased Expression of TL 1A Protein. PLoS One. 4:e4719 (2009). [cited by applicant]
Prometheus Biosciences, Inc. Amendment No. 1 to Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Mar. 8, 2021 (245 pages). [cited by applicant]
Prometheus Biosciences, Inc. Amendment No. 2 to Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Mar. 11, 2021 (245 pages). [cited by applicant]
Prometheus Biosciences, Inc. Form 10K Annual Report as filed with the Securities and Exchange Commission on Feb. 28, 2023 (129 pages). [cited by applicant]
Prometheus Biosciences, Inc. Form 10K Annual Report as filed with the Securities and Exchange Commission on Mar. 9, 2022 (125 pages). [cited by applicant]
Prometheus Biosciences, Inc. Form 10-K/A Annual Report (Amendment No. 1) as filed with the Securities and Exchange Commission on Apr. 28, 2023 (42 pages). [cited by applicant]
Prometheus Biosciences, Inc. Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Mar. 11, 2021 (4 pages). [cited by applicant]
Prometheus Biosciences: Transcriptional and Microbial Biomarkers of Response to Anti-TL1A Therapy in Ulcerative Colitis: The Phase 2a Tuscany Study. The European Crohn's and Colitis Organization conference from Feb. 12-… [cited by applicant]
Baskaran et al., Protective association of tumor necrosis factor superfamily 15 (TNFSF15) polymorphic haplotype with ulcerative colitis and Crohn's disease in an Indian population. PLoS One 9(12):e114665 (2014). [cited by applicant]
U.S. Appl. No. 15/931,452 Restriction Requirement dated Oct. 3, 2022. [cited by applicant]
Takedatsu et al.: TL1A (TNFSF15) Regulates the Development of Chronic Colitis By Modulating both T helper (TH) 1 and TH17 Activation; Gastroenterology; HHS Public Access; 135(2): 552-567 (2008). [cited by applicant]
Wallach et al.: Chapter 29: Insights into TL1A and IBD Pathogenesis, Advances in TNF Family Research—Conf—12th Biennial International Tumor Necrosis Factor Conference; [Advances in Experimental Medicine and Biology; ISS… [cited by applicant]
Brennan et al. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229:81-83, 1985. [cited by applicant]
Co-pending U.S. Appl. No. 18/546,947, filed Aug. 17, 2023. [cited by applicant]
Karlin and Altschul: Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes. Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990). [cited by applicant]
Maniatis et al., Isolation of high-molecular-weight, eukaryotic DNA from cells grown in tissue culture. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y., pp. 280-281 (1982). [cited by applicant]
Stahle, et al. Multivariate data analysis and experimental design in biomedical research. Prog. Med. Chem., vol. 25, Chapter 6, 291-338, 1988. [cited by applicant]
U.S. Appl. No. 17/682,922 Office Action dated Dec. 14, 2023. [cited by applicant]
Wold, et al. PLS-regression: a basic tool of chemometrics. Chemom. Intell. Lab Syst. 2001, 58: 109-130. [cited by applicant]
Al-Lazikani, Bissan, et al., Standard Conformations for the Canonical Structures of Immunoglobulins. Journal of Molecular Biology 273(4):927-948 (1997). [cited by applicant]
Andiappan, et al. Evaluating the transferability of Hapmap SNPs to a Singapore Chinese population. BMC Genetics, 11.36 (2010). [cited by applicant]
Bauer et al., A genetic enrichment for mutations constructed by oligodeoxynucleotide-directed mutagenesis. Gene, 37:73-81, 1985. [cited by applicant]
Bhattacharya et al.: Impact of genetic variation on three dimensional structure and function of proteins. PLoS One. 12(3):e0171355 (2017). [cited by applicant]
Bork: Go hunting in sequence databases but watch out for the traps. Trends in Genetics. 12(10):425-427 (1996). [cited by applicant]
Bork: Powers and Pitfalls in Sequence Analysis: The 70% Hurdle. Genome Res. 10:398-400 (2000). [cited by applicant]
Brennan et al.: Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin fragments. Science 229:81-83 (1985). [cited by applicant]
Brenner: Errors in genome annotation. Trends in Genetics. 15:132-133 (1999). [cited by applicant]
Brorson et al.: Mutational Analysis of Avidity and Fine Specifictiy of Anti-Levan Antibodies. J. Immunol. 163:6694-6701 (1999). [cited by applicant]
Bruggemann et al.: Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies. J. Exp. Med. 166:1351-1361 (1987). [cited by applicant]
Casset et al.: A peptide mimetic of an anti-CD4 monoclonal antibody by rationale design. Biochem Biophys Res Comm. 307:198-205 (2003). [cited by applicant]
Chen et al.: Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 293:865-881 (1999). [cited by applicant]
Clynes et al. Fc receptors are required in passive and active immunity to melanoma. PNAS USA 95(2):652-656 (1998). [cited by applicant]
Colman: Effects of amino acid sequence changes on antibody-antigen interactions. Research in Immunol. 145:33-36 (1994). [cited by applicant]
Craik, Charles. Use of oligonucleotides for site-specific mutagenesis. BioTechniques 1985 :12-19, 1985. [cited by applicant]
DePascalis et al.: Grafting and “abbreviated” complementarity-determining regions containing specificity-determining residues essential for Ligand contact to engineer a less immunogenic humanized monoclonal antibody. J.… [cited by applicant]
Doerks et al.: Protein annotation: detective work for function prediction. Trends in Genetics. 14:248-250 (1998). [cited by applicant]
Fenton et al.: Rheostat positions: a new classification of protein positions relevant to pharmacogenomics. Medicinal Chem Res. 29:1133-1146 (2020). [cited by applicant]
Gazzano-Santoro et al.: A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J Immunol Methods 202(2):163-171 (1997). [cited by applicant]
Guo et al.: Protein tolerance to random amino acid change. Proc Natl Acad Sci. USA 101(25):9205-9210 (2004). [cited by applicant]
Holm et al.: Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Mol Immunol 44:1075-1084 (2007). [cited by applicant]
Honegger et al.: Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modeling and Analysis Tool. Journal of Molecular Biology 309(3):657-670 (2001). [cited by applicant]
Jang et al.: The structural basis for DNA binding by an anti-DNA autobody. Mol Immunol 35:1207-1217 (1998). [cited by applicant]
Kabat et al.: Sequences of Proteins of Immunological Interest, NIH Publication No. 91-3242. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health 1:647-669 (1991). [cited by applicant]
Karlin et al.: Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences. Proceedings of the National Academy of Sciences of the United States of America 90(12):5873-5877 (1993). [cited by applicant]
Karlin et al.: Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes. Proceedings of the National Academy of Sciences of the United States of America 87(6):22… [cited by applicant]
Lefranc et al.: IMGT Unique Numbering for Immunoglobulin and T Cell Receptor Variable Domains And Ig Superfamily V-like Domains. Developmental & Comparative Immunology 27(1):55-77 (2003). [cited by applicant]
MacCallum et al.: Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography. Journal of Molecular Biology 262(5):732-745 (1996). [cited by applicant]
Patel, et al. An improved assay for antibody dependent cellular cytotoxicity based on time resolved fluorometry. J Immunol Methods. Jul. 17, 1995;184(1):29-38. [cited by applicant]
PAUL: Fundamental Immunology. 3rd Edition. Raven Press. New York. Chapter 8. pp. 292-295 (1993). [cited by applicant]
PCT Patent Application No. PCT/US2024/016224 filed Feb. 16, 2024. [cited by applicant]
PCT Patent Application No. PCT/US2024/016257 filed Feb. 16, 2024. [cited by applicant]
PCT Patent Application No. PCT/US2024/016264 filed Feb. 16, 2024. [cited by applicant]
PCT Patent Application No. PCT/US2024/016280 filed Feb. 16, 2024. [cited by applicant]
PCT/US2021/058979 International Preliminary Report on Patentability dated May 25, 2023. [cited by applicant]
PCT/US2021/058979 International Search Report and Written Opinion dated Apr. 11, 2022. [cited by applicant]
Sela-Culang et al.: The structural basis of antibody-antigen recognition. Front Immunol. 4(302):1-13 (2013). [cited by applicant]
Skolnick et al.: From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol. 18(1):34-39 (2000). [cited by applicant]
Smith et al.: The challenges of genome sequence annotation or “the devil is in the details”. Nature Biotechnol. 15:1222-1223 (1997). [cited by applicant]
Sotos, et al. The Transitivity Misconception of Pearson's Correlation Coefficient. Statistics Education Research Journal. 8(2):33-55 (2009). [cited by applicant]
Tokuriki et al.: Stability effects of mutations and protein evolvability. Curr Opin Structural Biol. 19:596-604 (2009). [cited by applicant]
U.S. Appl. No. 18/546,938, filed Feb. 27, 2024. [cited by applicant]
U.S. Appl. No. 18/546,947, filed Aug. 27, 2023. [cited by applicant]
U.S. Appl. No. 18/557,551, filed Oct. 26, 2023. [cited by applicant]
U.S. Appl. No. 17/931,049 Office Action dated Mar. 12, 2024. [cited by applicant]
Vajdos et al.: Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol. 320:415-428 (2002). [cited by applicant]
Vasudevan et al.: A single amino acid change in the binding pocket alters specificity of an anti-integrin antibody AP7.4 as revealed by its crystal structure. Blood Cells Mol Diseases. 32:176-181 (2004). [cited by applicant]
Walder et al. Oligodeoxynucleotide-directed mutagenesis using the yeast transformation system. Gene 42:133-139, 1986. [cited by applicant]
Whitelegg et al.: WAM: An Improved Algorithm for Modelling Antibodies on the WEB. Protein Engineering 13(12):819-824 (2000). [cited by applicant]
Wilkinson, et al. Antibody-dependent cell-mediated cytotoxicity: a flow cytometry-based assay using fluorophores. J Immunol Methods. Dec. 1, 2001;258(1-2):183-91. [cited by applicant]
Wisecarver et al.: A method for determination of antibody-dependent cellular cytotoxicity (ADCC) of human peripheral mononuclear cells. J Immunol Methods. May 23, 1985;79(2):277- 282. [cited by applicant]
Wu et al.: Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J Mol Biol. 294:151-162 (1999). [cited by applicant]
Zhang et al.: Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle. mAbs 7(1):42-52 (2015). [cited by applicant]
Cited By (1)
US 12,391,752